Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC

BSE9201.05111.35 (+1.23 %)

PREV CLOSE ( ) 9089.70

OPEN PRICE ( ) 9044.35

BID PRICE (QTY) 9192.50 (2)

OFFER PRICE (QTY) 9208.65 (3)

VOLUME 486

TODAY'S LOW / HIGH ( )8999.70 9246.65

52 WK LOW / HIGH ( )6222.35 10653.05

NSE9202.5089.5 (+0.98 %)

PREV CLOSE( ) 9113.00

OPEN PRICE ( ) 9075.00

BID PRICE (QTY) 9190.50 (2)

OFFER PRICE (QTY) 9199.50 (4)

VOLUME 5353

TODAY'S LOW / HIGH( ) 8994.00 9242.00

52 WK LOW / HIGH ( )6220 10691

Select year

Particulars

Mar 2025

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Operational & Financial Ratios

Earnings Per Share (Rs)

46.30

64.60

39.72

24.64

37.32

CEPS(Rs)

62.29

70.58

46.22

31.42

45.37

DPS(Rs)

32.00

24.00

16.00

10.00

2.00

Book NAV/Share(Rs)

305.28

283.45

234.45

203.78

181.83

Tax Rate(%)

25.98

26.43

25.96

25.82

26.59

Margin Ratios

Core EBITDA Margin(%)

14.74

14.17

16.39

10.65

16.58

EBIT Margin(%)

9.16

16.95

13.37

10.38

15.69

Pre Tax Margin(%)

9.08

16.86

13.31

10.26

15.56

PAT Margin (%)

6.72

12.40

9.85

7.61

11.42

Cash Profit Margin (%)

9.04

13.55

11.47

9.70

13.88

Performance Ratios

ROA(%)

7.43

13.35

9.37

6.65

11.31

ROE(%)

15.73

24.95

18.13

12.78

22.83

ROCE(%)

21.29

33.94

24.49

17.36

31.24

Asset Turnover(x)

1.11

1.08

0.95

0.87

0.99

Sales/Fixed Asset(x)

8.51

7.11

5.79

4.93

5.58

Working Capital/Sales(x)

2.69

2.26

2.23

2.17

2.59

Efficiency Ratios

Fixed Capital/Sales(x)

0.12

0.14

0.17

0.20

0.18

Receivable days

35.81

36.53

35.03

38.57

37.62

Inventory Days

82.25

58.60

59.85

67.64

72.59

Payable days

124.39

131.27

214.92

220.48

246.52

Valuation Parameters

PER(x)

185.90

82.35

81.76

103.71

80.66

PCE(x)

138.16

75.38

70.26

81.33

66.34

Price/Book(x)

28.19

18.77

13.85

12.54

16.55

Yield(%)

0.37

0.45

0.49

0.39

0.07

EV/Net Sales(x)

12.22

9.88

7.60

7.37

8.82

EV/Core EBITDA(x)

71.21

58.36

39.84

58.85

48.37

EV/EBIT(x)

132.93

57.96

56.54

70.72

55.96

EV/CE(x)

27.23

17.97

12.94

11.62

8.21

M Cap / Sales

12.54

10.27

8.09

7.93

9.25

Growth Ratio

Net Sales Growth(%)

32.48

29.17

24.50

-0.98

-2.19

Core EBITDA Growth(%)

34.37

14.66

89.44

-31.94

10.94

EBIT Growth(%)

-28.50

63.84

60.41

-34.47

11.35

PAT Growth(%)

-28.34

62.66

61.19

-33.98

29.21

EPS Growth(%)

-28.34

62.66

61.19

-33.98

29.21

Financial Stability Ratios

Total Debt/Equity(x)

0.00

Current Ratio(x)

1.70

2.23

1.93

1.95

1.84

Quick Ratio(x)

1.10

1.74

1.54

1.59

1.42

Interest Cover(x)

108.10

183.95

213.86

88.41

117.60

Total Debt/Mcap(x)

0.00